None listed
Conditions
Brief summary
The aim of the study is to assess the efficacy of a natural treatment for the symptoms of the adverse after effects f alcohol. The product Rapid Recovery has been developed based on the scientifically supported rationales using several methods of reducing acetaldehyde ( a major metabolite of alcohol) toxicity which is believed to be a major mediator in the adverse after effects of alcohol consumption. Adverse effects of alcohol consumption will be measured the following day using visual analog scales of validated symptoms. In addition blood alcohol concentrations will be measured prior to commencing the study and at the end of the evening drinking and immediately prior to undertaking visual analog scales. Blood sampling will be performed on the first night of the trial and then on the morning after alcohol has been consumed. There have been reports that that there may be an inflammatory response due to acetaldehyde toxicity.
Interventions
750mg once daily
Administration over two days 2 capsules first dose at the end of the consumption of alcohol 2 capsules the second dose the following morning
First dose given at site by site staff.
Second dose recorded by patient time and date and returned to staff the following day
There is a seven day washout period
Each capsule contains l-cysteine hydrochloride 80mg, ascorbic acid 400mg, thiamine hydrochloride 80mg, pyridixine hydrochloride 20mg
Alcohol was consumed 1.3 mg per kilogram for e
750mg once daily Administration over two days 2 capsules first dose at the end of the consumption of alcohol 2 capsules the second dose the following morning First dose given at site by site staff. Second dose recorded by patient time and date and returned to staff the following day There is a seven day washout period Each capsule contains l-cysteine hydrochloride 80mg, ascorbic acid 400mg, thiamine hydrochloride 80mg, pyridixine hydrochloride 20mg Alcohol was consumed 1.3 mg per kilogram for each participant all drinks had the time and amount recorded so that they could be repeated on the following study day
Sponsors
Phoenix Pharmaceuticals Pty Ltd
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
25 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Normal males and females who have suffered a hangover in the previous year
Exclusion criteria
Have either a drug or alcohol problem or any medical condition that is considered by the Medical practitioner as unsuitable
Outcome results
None listed